| Autor: |
Pandey PR; Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA., Tomney A; Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA., Woon MT; Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA., Uth N; Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA., Shafighi F; Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA., Ngabo I; Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA., Vallabhaneni H; Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA., Levinson Y; Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA., Abraham E; Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA., Friedrich Ben-Nun I; Cell and Gene Therapy Research and Development, Lonza Inc., Rockville, MD 20850, USA. |
| Abstrakt: |
Industrialization of stem-cell based therapies requires innovative solutions to close the gap between research and commercialization. Scalable cell production platforms are needed to reliably deliver the cell quantities needed during the various stages of development and commercial supply. Human pluripotent stem cells (hPSCs) are a key source material for generating therapeutic cell types. We have developed a closed, automated and scalable stirred tank bioreactor platform, capable of sustaining high fold expansion of hPSCs. Such a platform could facilitate the in-process monitoring and integration of online monitoring systems, leading to significantly reduced labor requirements and contamination risk. hPSCs are expanded in a controlled bioreactor using perfused xeno-free media. Cell harvest and concentration are performed in closed steps. The hPSCs can be cryopreserved to generate a bank of cells, or further processed as needed. Cryopreserved cells can be thawed into a two-dimensional (2D) tissue culture platform or a three-dimensional (3D) bioreactor to initiate a new expansion phase, or be differentiated to the clinically relevant cell type. The expanded hPSCs express hPSC-specific markers, have a normal karyotype and the ability to differentiate to the cells of the three germ layers. This end-to-end platform allows a large scale expansion of high quality hPSCs that can support the required cell demand for various clinical indications. |
